CA2004364C - Oligonucleotides "antisense" de c-myb oncogene et leur utilisation - Google Patents

Oligonucleotides "antisense" de c-myb oncogene et leur utilisation

Info

Publication number: CA2004364C
Authority: CA; Canada
Prior art keywords: myb; cells; tct tcg; ggg tct; use according
Prior art date: 1989-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2004364

Other languages

English (en)

Other versions

CA2004364A1 (fr

Inventor

Alan M. Gewirtz

Bruno Calabretta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Temple Univ School of Medicine

Original Assignee

Temple Univ School of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-09

Filing date

1989-12-01

Publication date

1999-08-31

1989-10-27 Priority claimed from US07/427,659 external-priority patent/US5098890A/en

1989-12-01 Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine

1991-03-15 Publication of CA2004364A1 publication Critical patent/CA2004364A1/fr

1999-08-31 Application granted granted Critical

1999-08-31 Publication of CA2004364C publication Critical patent/CA2004364C/fr

2009-12-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 title claims abstract description 103
239000000074 antisense oligonucleotide Substances 0.000 title abstract description 43
238000012230 antisense oligonucleotides Methods 0.000 title abstract description 43
108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract description 33
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 claims abstract description 102
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 56
108020004999 messenger RNA Proteins 0.000 claims abstract description 40
239000002773 nucleotide Substances 0.000 claims abstract description 30
125000003729 nucleotide group Chemical group 0.000 claims abstract description 30
230000000295 complement effect Effects 0.000 claims abstract description 29
101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 claims abstract description 20
208000002250 Hematologic Neoplasms Diseases 0.000 claims abstract description 12
230000001506 immunosuppresive effect Effects 0.000 claims abstract description 6
206010062016 Immunosuppression Diseases 0.000 claims abstract description 5
230000001939 inductive effect Effects 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 154
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 46
210000002798 bone marrow cell Anatomy 0.000 claims description 20
108091081024 Start codon Proteins 0.000 claims description 7
230000014621 translational initiation Effects 0.000 claims description 6
108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
108020004705 Codon Proteins 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
201000005787 hematologic cancer Diseases 0.000 claims 4
230000000692 anti-sense effect Effects 0.000 abstract description 91
210000001185 bone marrow Anatomy 0.000 abstract description 30
238000010926 purge Methods 0.000 abstract description 25
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 14
239000003795 chemical substances by application Substances 0.000 abstract description 11
108700021654 myb Genes Proteins 0.000 abstract description 6
238000000034 method Methods 0.000 description 28
208000032839 leukemia Diseases 0.000 description 23
210000004881 tumor cell Anatomy 0.000 description 16
230000000694 effects Effects 0.000 description 15
210000003958 hematopoietic stem cell Anatomy 0.000 description 15
206010028980 Neoplasm Diseases 0.000 description 14
230000012010 growth Effects 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
102100030780 Transcriptional activator Myb Human genes 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 11
239000000203 mixture Substances 0.000 description 11
230000014616 translation Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
210000003969 blast cell Anatomy 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
230000035945 sensitivity Effects 0.000 description 10
238000013519 translation Methods 0.000 description 10
210000001072 colon Anatomy 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
210000000130 stem cell Anatomy 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000005755 formation reaction Methods 0.000 description 7
230000000977 initiatory effect Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000013589 supplement Substances 0.000 description 7
230000035899 viability Effects 0.000 description 7
102000052575 Proto-Oncogene Human genes 0.000 description 6
108700020978 Proto-Oncogene Proteins 0.000 description 6
230000007423 decrease Effects 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
229920000609 methyl cellulose Polymers 0.000 description 6
239000001923 methylcellulose Substances 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
208000000389 T-cell leukemia Diseases 0.000 description 5
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
230000005757 colony formation Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
210000005170 neoplastic cell Anatomy 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000004114 suspension culture Methods 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 4
229940034982 antineoplastic agent Drugs 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
230000002489 hematologic effect Effects 0.000 description 4
230000001744 histochemical effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000025113 myeloid leukemia Diseases 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
208000031223 plasma cell leukemia Diseases 0.000 description 4
239000003104 tissue culture media Substances 0.000 description 4
238000010600 3H thymidine incorporation assay Methods 0.000 description 3
208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102000000646 Interleukin-3 Human genes 0.000 description 3
108010002386 Interleukin-3 Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000011132 hemopoiesis Effects 0.000 description 3
230000000984 immunochemical effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000006194 liquid suspension Substances 0.000 description 3
238000002515 oligonucleotide synthesis Methods 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108010047620 Phytohemagglutinins Proteins 0.000 description 2
235000013290 Sagittaria latifolia Nutrition 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000118 anti-neoplastic effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
235000015246 common arrowhead Nutrition 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000012252 genetic analysis Methods 0.000 description 2
210000000224 granular leucocyte Anatomy 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
210000001621 ilium bone Anatomy 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000001237 metamyelocyte Anatomy 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000001885 phytohemagglutinin Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108020004519 Antisense Oligoribonucleotides Proteins 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241001521739 Colon Species 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102100020873 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
208000002774 Paraproteinemias Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
101710187995 Transcriptional activator Myb Proteins 0.000 description 1
206010060872 Transplant failure Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
208000024340 acute graft versus host disease Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
201000005179 adrenal carcinoma Diseases 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
238000007605 air drying Methods 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002825 antisense oligoribonucleotide Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010370 cell cloning Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000009028 cell transition Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
GYWXIPVJXCUFMP-UHFFFAOYSA-N ethyl 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(=O)OCC)CS1 GYWXIPVJXCUFMP-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
102000053563 human MYC Human genes 0.000 description 1
102000054896 human PML Human genes 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
108700024542 myc Genes Proteins 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
239000006163 transport media Substances 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2004364 1989-09-09 1989-12-01 Oligonucleotides "antisense" de c-myb oncogene et leur utilisation Expired - Lifetime CA2004364C (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US40802689A	1989-09-09	1989-09-09
US408,026		1989-09-09
US07/427,659 US5098890A (en)	1988-11-07	1989-10-27	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US427,659		1989-10-27

Publications (2)

Publication Number	Publication Date
CA2004364A1 CA2004364A1 (fr)	1991-03-15
CA2004364C true CA2004364C (fr)	1999-08-31

Family

ID=27020110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2004364 Expired - Lifetime CA2004364C (fr)	1989-09-09	1989-12-01	Oligonucleotides "antisense" de c-myb oncogene et leur utilisation

Country Status (1)

Country	Link
CA (1)	CA2004364C (fr)

1989
- 1989-12-01 CA CA 2004364 patent/CA2004364C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2004364A1 (fr)	1991-03-15

Legal Events

Date	Code	Title	Description
1996-11-07	EEER	Examination request
2009-12-01	MKLA	Lapsed
2012-12-02	MKEC	Expiry (correction)	Effective date: 20121202

Publication	Publication Date	Title
US5098890A (en)	1992-03-24	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en)	1992-02-11	Methods and compositions for treatment of cancer using oligonucleotides
US5652222A (en)	1997-07-29	Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
WO1998014615A1 (fr)	1998-04-09	Modulation oligonucleotidique antisens de l'expression genique a glyproteine-p resistant a plusieurs drogues (mdr)
EP0772621A2 (fr)	1997-05-14	Oligonucleotide a activite anti-gene mdr-1
DE69330137T2 (de)	2001-11-15	Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
AU2011301712B2 (en)	2016-07-28	Method for reducing the number of certain circulating leukocytes in a human subject
KR100695677B1 (ko)	2007-03-15	안티센스 조성물 및 암-치료 방법
WO1993003770A1 (fr)	1993-03-04	Procede et compositions utilises pour la reprogrammation cellulaire
US5612212A (en)	1997-03-18	Selective inhibition of cell proliferation by vav antisense oligonucleotides
CA2004364C (fr)	1999-08-31	Oligonucleotides "antisense" de c-myb oncogene et leur utilisation
CA1340369C (fr)	1999-02-02	Oligonucleotides antisens pour le proto-oncogene c-myb et utilisations correspondantes
US5989849A (en)	1999-11-23	Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
CA2123611A1 (fr)	1993-05-27	Traitement du melanome avec des oligonucleotides antisens contre le proto-oncogene c-myb
JP2003527096A (ja)	2003-09-16	Ｃ−ｍｙｃアンチセンス処理した造血幹細胞組成物および方法
WO1992019252A1 (fr)	1992-11-12	Oligonucleotides non codants du proto-ontogene c-kit et leurs utilisations
WO1994004137A1 (fr)	1994-03-03	Oligonucleotides non codant complementaires du proto-oncogene de cycline d1